The overlap syndrome: combination of the autoimmune hepatitis with the primary biliary cholangitis
Journal Title: Сучасна гастроентерологія - Year 2019, Vol 0, Issue 1
Abstract
The overlap syndrome in hepatology traditionally defined as the simultaneous presence in a patient of clinical or laboratory signs of two different autoimmune liver diseases. The most common combination is autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). In this case, a differential diagnosis based on clinical signs is often difficult. Routine laboratory tests indicate the presence of both parenchymal and cholestatic variants of liver damage. There are no international criteria that clearly define the case of overlap syndrome. There is a set of descriptive criteria presented by the International Group for the Study of Autoimmune Hepatitis (IAIHG), which includes not only biochemical and serological indicators, but also the histological examination of the liver. Usually, in the case of overlap syndrome, the course of the liver disease is more aggressive. For example, in case of combination of PBC and AIH, severe fibrosis is more frequent at the time of diagnosis, hepatocellular insufficiency develops faster and indications for liver transplantation appear earlier. The management of patients with overlap syndrome in each case is individual and focused on the prevailing component: autoimmune hepatitis or primary biliary cholangitis. The feasibility of combined immunosuppressive therapy and ursodeoxycholic acid (UDCA) has not been completely clarified. Moreover, this applies both to individual publications and to the consensus documents of the International Group for the Study of Autoimmune Hepatitis. In the absence of a sustained response in the case of a combination therapy, tactics may be revised in favor of monotherapy with UDCA, given the high percentage of complications with continued treatment with immunosuppressants.
Authors and Affiliations
O. Ye. Zaytseva, S. L. Kushnir, O. O. Diadyk
Keywords
Related Articles
- EP ID EP508487
- DOI 10.30978/MG-2019-1-71
- Views 150
- Downloads 0
The role of serum biomarkers in the diagnosis of nonalcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is a disease characterized by liver steatosis and the ability to progress to more serious pathological conditions, including non-alcoholic steatohepatitis (NASH), fibrosis and ci...
The peculiarities of some gastroenterological diseases in elderly patients
The data presented in the paper were based on the recent investigations and currentrecommendations. The pathological changes in the gastroenterological profile are proved to be most prevalent in subjects aged 65 years an...
The new possibilities for the treatment of patients with chronic constipation
Objective — to analyze the efficacy of using the herbal drug EasyDo in patients with chronic constipation. Materials and methods. The observations involved 40 patients with chronic constipation, aged 18 to 65 years, who...
Peculiarities of the clinical course and visceral adipose tissue in patients with non-alcoholic fatty liver disease against the background of metabolic syndrome
Objective — to study the peculiarities of metabolic disturbances in patients with nonalcoholic fatty liver disease (NAFLD) and their role in the development and progression of liver steatosis. Materials and methods. Inv...
Clinical Practice Guidelines of European Association for the Study of the Liver (EASL) on nutrition in chronic liver disease. Part 3
_